Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDeltex Medical Regulatory News (DEMG)

Share Price Information for Deltex Medical (DEMG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.12
Bid: 0.11
Ask: 0.13
Change: 0.005 (4.35%)
Spread: 0.02 (18.182%)
Open: 0.115
High: 0.12
Low: 0.115
Prev. Close: 0.115
DEMG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of Meeting

30 Oct 2009 11:03

RNS Number : 6705B
Deltex Medical Group PLC
30 October 2009
 



30 October 2009

Deltex Medical Group plc 

 

 

("Deltex Medical" or the "Company")

Result of General Meeting 

On 14 October 2009 Deltex Medical Group plc, the global leader in oesophageal Doppler monitoring ("ODM"), announced the conditional placing of 22,222,222 new ordinary shares of 1p each ("Ordinary Shares") in the Company (the "Placing"). The Placing was conditional, inter alia, upon the Company obtaining approval from its shareholders to grant the Directors authority to allot the Ordinary Shares and to disapply statutory pre-emption rights (the "Resolutions"). In this connection, a General Meeting ("GM") of Deltex Medical shareholders was held at 9.00 a.m. today.

Deltex Medical is pleased to announce that the Resolutions were approved at the GM. 

Accordingly, application has been made for these shares to be admitted to trading on AIM. The shares rank pari passu with the existing issued shares of the Company and dealings are expected to commence on 2 November 2009. 

 

Following this, the total number of voting rights in issue will be 124,598,597.

For further information, please contact:- 

  

Deltex Medical Group plc 01243 774 837 

Nigel Keen, Chairman  njk@deltexmedical.com 

Ewan Phillips, Chief Executive eap@deltexmedical.com 

Paul Mitchell, Finance Director pjm@deltexmedical.com 

 

 

Nominated Adviser & Broker 

Arden Partners plc 020 7398 1600 

Chris Hardie chris.hardie@arden-partners.com 

Matthew Armitt matthew.armitt@arden-partners.com 

 

 

Kreab Gavin Anderson 020 7554 1400 

Deborah Walter  dwalter@kreabgavinanderson.com 

Robert Speed  rspeed@kreabgavinanderson.com 

 

 

Notes for Editors 

Deltex Medical manufactures and markets the CardioQ-ODM(TM) monitor, which uses

disposable ultra-sound probes inserted into the oesophagus to determine the amount of blood being pumped around the body - 'circulating blood volume'. 

Reduced circulating blood volume is known as hypovolaemia, which leads to insufficient oxygen being delivered to the organs. This causes medical complications including peripheral and major organ failure which can lead to death. Hypovolaemia, which is akin to severe dehydration, affects virtually every patient having surgery because of the combined effects of pre-operative starvation, the impact of the anaesthetic agents and trauma from the surgery itself. Using fluids and drugs, guided by the CardioQ-ODM, to optimise the amount of circulating blood significantly reduces post-operative complications allowing patients to make a faster, more complete recovery and return home earlier. 

 

The CardioQ-ODM incorporates the Company's proprietary software and a small diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is used for transmitting and receiving an ultra-sound signal. By using this technology, the CardioQ-ODM provides clinicians with the ability to haemodynamically optimise critically ill patients and those undergoing routine moderate to major surgery through the controlled administration of fluid and drugs. Haemodynamic optimisation has been scientifically proven to improve the speed and quality of patient recovery and reduce hospital stay. 

 

There are already over 1,750 CardioQ-ODMs currently in use in hospitals worldwide and distribution arrangements are in place in over 30 countries. In addition, there are currently more than 200 clinical publications on the use of the CardioQ-ODM which have repeatedly:- 

 

* Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works 

* Proved that the CardioQ-ODM works in a wide range of surgical procedures 

Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. 

 

The SupraQ(TM) is an entirely non-invasive device which uses an ultrasound probe held at the base of the patient's neck to track the flow of blood in the aorta; it presents the same data as the CardioQ-ODM in a similar format and is used for taking snapshots or monitoring over short periods. 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ROMFBLFXKBBBFBL
Date   Source Headline
23rd Apr 20087:01 amRNSNext Generation of CardioQ
22nd Apr 200812:10 pmRNSHolding(s) in Company
18th Apr 20087:00 amRNSCompletion of Funding Package
15th Apr 20087:01 amRNSCardioQ update
14th Apr 20087:01 amRNSCardioQ update
7th Apr 20087:01 amRNSFinal Results
7th Apr 20087:01 amRNSNew Non-Executive Director
3rd Apr 20087:00 amRNSCardioQ update
2nd Apr 20087:01 amRNSCardioQ update
28th Mar 20087:02 amRNSNTAH update
26th Mar 20087:02 amRNSCardioQ update
20th Mar 20087:00 amRNSNotice of Results
3rd Mar 20083:22 pmRNSODM meta - analysis
25th Jan 20083:58 pmRNSDirector/PDMR Shareholding
23rd Jan 20087:01 amRNSPositive Scientific Review
23rd Jan 20087:01 amRNSPre-close update
18th Jan 200811:41 amRNSHSJ Article
26th Nov 20079:03 amRNSDirector/PDMR Shareholding
21st Nov 20077:02 amRNSCardioQ Product Endorsement
31st Oct 20072:15 pmRNSTotal Voting Rights
22nd Oct 20079:01 amRNSHolding(s) in Company
16th Oct 20074:03 pmRNSAdditional Listing
1st Oct 20077:06 amRNSCardioQ announcement
25th Sep 200711:00 amRNSInterim Results - Replacement
25th Sep 20077:03 amRNSInterim Results
16th Aug 20073:53 pmRNSAIM Rule 26 Information
31st Jul 20073:29 pmRNSTotal Voting Rights
25th Jul 200711:30 amRNSRecommendation for CardioQ
11th Jul 20077:01 amRNSTrading Statement
5th Jul 20073:30 pmRNSImproving Surgical Outcomes
29th Jun 20073:34 pmRNSDirector/PDMR Shareholding
29th Jun 20073:26 pmRNSAdditional Listing
29th Jun 20078:52 amRNSTotal Voting Rights
28th Jun 20077:04 amRNSNew Clinical Evidence
22nd Jun 20077:01 amRNSAdditional Listing
19th Jun 20073:02 pmRNSHolding(s) in Company
14th Jun 20074:02 pmRNSAdditional Listing
7th Jun 20077:03 amRNSNew CardioQ Data
5th Jun 20077:02 amRNSUS Reimbursement Update
31st May 20078:49 amRNSTotal Voting Rights
23rd May 20077:32 amRNSUS Reimbursement Coverage
22nd May 20078:31 amRNSAdditional Listing
3rd May 20071:06 pmRNSIssue of Equity
3rd May 200710:25 amRNSAGM Statement
12th Apr 20077:01 amRNSUCLH adopts CardioQ
28th Mar 20078:00 amRNSHealth Technology Assessment
21st Mar 20072:53 pmRNSHolding(s) in Company
15th Mar 20077:05 amRNSUS Government HTA Published
15th Mar 20077:01 amRNSFinal Results
9th Mar 200712:35 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.